Octocog Alfa Drug Aliquot | Factor VIII | Therapeutic Recombinant protein

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Octocog Alfa are now available as research consumables.

Octocog Alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Octocog Alfa Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Advate® / Octocog Alfa Reference Product

Drug nameAdvate®
INNOctocog Alffa
API typeOctocog alfa (human coagulation factor VIII (rDNA)) is a purified protein that has 2332 amino acids.
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared without the addition of any (exogenous) human- or animal-derived protein in the cell culture process, purification or final formulation.
Pharmacotherapeutic group
Antihemorrhagics, blood coagulation factor VIII
ATC code
Target of antibody
TNF alpha
General functionTreatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). Octocog Alfa is indicated in all age groups.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
When infused into a haemophilia patient, octocog alfa binds to endogenous von Willebrand Factor in the patient’s circulation. Activated factor VIII acts as a Cofactor for activated Factor IX, accelerating the conversion of Factor X to activated Factor X. Activated Factor X converts prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. The plasma levels of factor VIII are increased by replacement therapy, thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Takeda Manufacturing Austria AG
Industriestrasse 67
A-1221 Vienna
Marketing authorisation numbers

Marketing authorisation holder
Takeda Manufacturing Austria AG
Industriestrasse 67
A-1221 Vienna
Name of the manufacturer of the biological active substance
Baxalta Manufacturing Sàrl
Route de Pierre-à-Bot 111
CH-2000 Neuchâtel

Baxalta Manufacturing SARL
Singapore Branch
2A Woodlands Industrial Park D Street 2
Singapore 737779
Name and address of the manufacturer(s) responsible for batch releaseBaxalta Belgium Manufacturing SA
Boulevard René Branquart 80
B-7860 Lessines
Max shelf life
2 years
Storage conditions
2°C – 8°C
List of excipients
Powder: Mannitol, Sodium chloride, Histidine, Trehalose, Calcium chloride, Trometamol, Polysorbate 80, Glutathione (reduced)
Solvent: Sterilised water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.